Last reviewed · How we verify
Onychomycosis due to Trichophyton mentagrophytes
Approved treatments
- Jublia · Bausch Health
Jublia works by inhibiting the fungal enzyme lanosterol 14α-demethylase, which is essential for the production of ergosterol, a critical component of fungal cell membranes.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Onychomycosis due to Trichophyton mentagrophytes patent landscape — cliff calendar, originator estates, attackable patents
- Onychomycosis due to Trichophyton mentagrophytes treatment landscape brief
- Onychomycosis due to Trichophyton mentagrophytes treatment updates RSS
Frequently asked questions about Onychomycosis due to Trichophyton mentagrophytes
What drugs treat Onychomycosis due to Trichophyton mentagrophytes?
Tracked treatments include Jublia.
What is the treatment for Onychomycosis due to Trichophyton mentagrophytes?
Standard treatment for Onychomycosis due to Trichophyton mentagrophytes includes Jublia. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Onychomycosis due to Trichophyton mentagrophytes patent cliff · Onychomycosis due to Trichophyton mentagrophytes CI report
- Treatment: Jublia · Bausch Health
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing